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ABSTRACT
Objective To determine whether environmental control
using nocturnal temperature controlled laminar airﬂow
(TLA) treatment could improve the quality of life of
patients with persistent atopic asthma.
Design Randomised, double-blind, placebo-controlled,
parallel-group trial.
Setting Nineteen European asthma clinics.
Participants 312 patients aged 7e70 with inadequately
controlled persistent atopic asthma.
Main outcome measure Proportion of patients with an
increase of $0.5 points in asthma quality of life score
after 1 year of treatment.
Results TLA devices were successfully installed in the
bedrooms of 282 (90%) patients included in the primary
efﬁcacy analysis. There was a difference in treatment
response rate between active (143 of 189, 76%) and
placebo (56 of 92, 61%) groups, difference 14.8% (95%
CI 3.1 to 26.5, p¼0.02).
3 In patients aged $12, on
whom the study was powered, the difference in
response rate was similar-active 106 of 143 (74%),
placebo 42 of 70 (60%), difference 14.1% (0.6 to 27.7,
p¼0.059). There was a difference between groups in
fractional exhaled nitric oxide change of  7.1 ppb
( 13.6 to  0.7, p¼0.03). Active treatment was
associated with less increase in cat-speciﬁc IgE than
placebo. There was no difference in adverse event rates
between treatment groups.
Conclusion Inhalant exposure reduction with TLA
improves quality of life, airway inﬂammation and
systemic allergy in patients with persistent atopic
asthma. TLA may be a treatment option for patients with
inadequately controlled persistent atopic asthma.
Trial registration number Clinical Trials NCT00986323.
INTRODUCTION
In patients with atopic asthma, the abnormal
immune response to inhalant allergens is an impor-
tant contributor to symptoms.
1 Studies undertaken
at high altitude suggest that long-term avoidance of
allergens and other exposures can lead to reduced
asthma symptoms.
2e6 Despite positive reports
from comprehensive home environmental control
programmes,
7 blinded placebo-controlled studies of
air ﬁlters and other single-device interventions have
failed to demonstrate signiﬁcant beneﬁt, suggesting
that the reduction in allergen exposure is insufﬁcient
to impact on airway inﬂammation.
89A new device
Protexo (Airsonett, Ängelholm, Sweden) has
recently been shown to markedly reduce levels of
inhaled allergen and other particles using tempera-
ture-controlled laminar airﬂow (TLA) (personal
communication, Dr Robin Gore, 2011). The device
distributes a ﬁltered cooled laminar airﬂow,
descending from an overhead position, which
displaces aeroallergens from the breathing zone. We
undertook a phase III multicentre randomised
controlled trial of nocturnal TLA treatment for
1 year to quantify the effect in patients with atopic
asthma on quality of life, symptom control, lung
function, airway inﬂammation and markers of
systemic allergy (speciﬁc IgE and eosinophil count).
METHODS
Participants
We enrolled patients with atopic asthma in a rand-
omised, controlled, parallel-group trial of add-on
treatment with TLA or placebo between April 2008
and February 2009. Patients were recruited from 19
European centres. Inclusion criteria were physi-
cian’s diagnosis of asthma $1 year prior to study;
age 7e70 years; Mini Asthma Quality of Life
Questionnaire (mini-AQLQ) or Paediatric Asthma
Quality of Life Questionnaire (PAQLQ) (together
termed ‘AQLQ’) score #5.5 at inclusion; allergic
sensitisation to a pet allergen (cat or dog) or house
dust mite demonstrated by speciﬁc IgE level
$0.70 kU/litre or positive skin prick test (weal
diameter $histamine control); daily inhaled corti-
costeroid $200 mg/day budesonide/beclomethasone
or $100 mg/day ﬂuticasone for last 6 months; and
features of partly controlled asthma according to
Global Initiative for Asthma (GINA) 2006.
10
Exclusion criteria were current active or passive
cigarette smoke exposure; inclusion in another
allergen avoidance programme or drug trial;
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Asthma and the environmenttreatment with allergen immunotherapy or omalizumab in
previous 2 years (1 year for children); inhaled corticosteroid dose
>1200 mg/day budesonide/beclomethasone or >1000 mg/day
ﬂuticasone. A history of frequent severe asthma exacerbations
was not an inclusion criterion for the study. The study was
approved by responsible institutional review boards and written
informed consent was obtained from all patients/parents.
An independent Data and Safety Monitoring Board reviewed
efﬁcacy and safety data.
Study intervention
Within 4 weeks from inclusion in the study, an active or placebo
TLA device was installed in the bedroom of each study patient.
The mode of action of the device is described in the online
supplementary material. Patients were asked to turn their device
on when they went to bed each night and off in the morning,
although the device automatically turned off after 12 h. Placebo
devices were identical to active devices, but their ﬁlter was
bypassed and circulating air not cooled. Treatment compliance
was assessed by an electronic counter within the machinery of
the devices, which recorded total number of device uses, and
total hours of use with the microcontroller MCU PIC18F6622
programmed by Voss Engineering AB, Sweden.
Randomisation and masking
Active or placebo treatment was allocated by the device instal-
lation technician according to a randomisation list generated by
an independent organisation (APL, Stockholm, Sweden) using
Design (Trombult Programming AB, Sweden) in blocks of nine
at a ratio of two active to one placebo. The study protocol
speciﬁed that randomisation would be stratiﬁed according to age
and gender, but this was not done due to an error in commu-
nication with the independent study statistician. The planned
stratiﬁcation of randomisation was however taken into consid-
eration during statistical analyses of outcome data. At the time
of device installation and servicing the technician ensured
patients and family members were absent from the bedroom
and masking of treatment allocation was maintained. Patients,
investigators, statisticians and the Trial Steering Committee
were masked to treatment allocations through the study.
Trial design
The study was a phase III multicentre, double-blind, placebo-
controlled, parallel-group trial. Patients were randomised to
receive add-on treatment with Protexo or a placebo device for
1 year. Asthma medications were kept unchanged for the ﬁrst
3 months, and thereafter adjusted to optimise asthma control by
local investigators according to GINA guidelines.
10 Patients were
monitored by medical assessments after 1, 3, 6, 9 and 12 months
of treatment, and via completion of a diary.
Outcome measures
The primary outcome measure was quality of life assessed by
the mini-AQLQ, or in children #11 years, the PAQLQ.
11 A
change of 0.5 is considered clinically signiﬁcant,
12 and the
primary outcome analysed was the proportion of patients with
a signiﬁcant increase in mini-AQLQ or PAQLQ score
(‘responders’) after 1 year of treatment. Secondary outcomes
were AQLQ score changes, objective measures of airway
inﬂammation (fractional exhaled nitric oxide; FENO), systemic
allergy (speciﬁc IgE levels to indoor aeroallergens and blood
eosinophil count), and airﬂow obstruction (forced expiratory
volume in 1 s, FEV1; forced expiratory ﬂow at 50% of vital
capacity, FEF50; peak expiratory ﬂow, PEF). Single-breath, online
measurement of FENO (NIOX MINO, Aerocrine AB, Stock-
holm, Sweden) was performed in accordance with the recom-
mendations of the American Thoracic Society.
13 Spirometry was
performed in accordance with international guidelines.
14 Blood
eosinophil counts were measured by local hospital laboratories,
and speciﬁc IgE levels using ImmunoCAP at a single laboratory
(Phadia, Denmark; lower limit 0.35 KU/litre). The study was
not designed primarily to evaluate effects of TLA on asthma
exacerbations, because a history of frequent or severe exacerba-
tions was not an inclusion criterion.
Statistical analysis
The study hypothesis was tested by examining the difference in
outcome variables between active and placebo groups at the end
of the 12-month treatment period. All patients who were
randomised and had $1 day of device treatment were included
in the intention-to-treat population and last observation carried
forward was used for missing data. Per protocol analyses
excluded patients with major protocol violations and/or docu-
mented treatment compliance <80%. Results were summarised
as mean scores or score changes 695% CI, or adjusted OR for
binary outcomes 695% CI. The country, gender, years since
asthma diagnosis, GINAtreatment step at baseline and AQLQ at
baseline were variates in the model for adjusted analyses, which
were undertaken using analysis of covariance (ANCOVA) for
continuous data, and logistic regression for binary data. We
calculated the sample size based on a minimum difference of
20% between treatment groups in the proportion of responders
(increase in AQLQ $0.5 points over the 12-month intervention),
and a responder rate of 20% in the placebo group. For 80% power
and a type I error of 5%, the sample size needed is 186. Allowing
for 20% loss to follow-up we planned to recruit 234 patients
aged $12 years, and a proportionate number of patients aged
<12. Planned subgroup analyses were undertaken by age, by
asthma treatment intensity at baseline (GINA treatment step),
for those with poor symptom control at baseline (Asthma
Control Test; ACT<18) and for those with a combination of
high-treatment intensity (GINA 4) and poor symptom control
at baseline, where guidelines recommend stepping up treat-
ment.
15 16 An interim analysis was undertaken by the Data and
Safety Monitoring Board after all participants reached 3 months,
which included the primary outcome measure and safety. No
action was taken after interim analysis as no safety issues were
reported and early stopping criteria were not met.
Role of the funding source
Airsonett AB sponsored the trial. The Trial Steering Committee
designed the study and statistical analysis plan. Data were
analysed by an independent statistician Fredrik Hansson
(Commitum AB). All authors had full access to data and anal-
yses, and vouch for the report’s accuracy and completeness.
RESULTS
Three hundred and twelve patients from six countries were
randomly allocated to treatment. Treatment groups had similar
baseline demographic and clinical characteristics (table 1).
Figure 1 shows the ﬂow of patients through the study. A total of
282 of 312 (90%) randomised patients had a study device
successfully installed in their bedroom, and were therefore
eligible for primary efﬁcacy analysis. Airborne particle counts
and mattress dust allergen levels during the study are described
in the online supplementary material.
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Asthma and the environmentEffects of TLA on asthma-related quality of life
Primary efﬁcacy analysis demonstrated a signiﬁcant difference in
AQLQ responder rate between active (143 of 189, 76%) and
placebo (56 of 92, 61%) groups after 1 yeardabsolute difference
14.8% (95% CI 3.1 to 26.5, p¼0.02; ﬁgure 2). Analysis of treat-
ment response rate in participants aged $12 years (on whom
the study was powered), showed a responder rate of 106 of 143
(74%) in the active group and 42 of 70 (60%) in the placebo
groupdabsolute difference 14.1% (95% CI 0.6 to 27.7, p¼0.059).
In per protocol analysis the difference between treatment groups
in responder rate was similar to intention-to-treat analysis, and
there were differences of similar magnitude in children <12
when analysed separately, and in those with severe asthma at
baseline judged by GINA-deﬁned treatment intensity (table 2).
10
The difference in responder rate was greatest in those with both
high-treatment intensity (GINA 4) and poor symptom control
(ACT<18) at baseline. Data were also analysed using a $1.0
point increase in AQLQ to deﬁne treatment response, and these
showed similar ﬁndings to the analyses using the predeﬁned
responder deﬁnition of $0.5 points (ﬁgure 2). In analysis of
treatment response rate without any imputation of missing
data, a treatment response was seen in 129 of 166 (78%) in the
TLA group at 12 months, and 50 of 79 (63%) in the placebo
groupdOR 1.87 (95% CI 1.05 to 3.34, p¼0.03). There was
a signiﬁcant difference between groups in change in the
symptom domain of AQLQ, with a mean 0.31 point (95% CI
0.01 to 0.61) greater increase after active versus placebo treat-
ment; 0.70 points (95% CI 0.13 to 1.26) in the subgroup with
high treatment intensity and poor symptom control at baseline.
Figure 3 shows absolute values for changes in AQLQ in the total
study population, and for those with highest treatment inten-
sity (GINA 4; 46% of the study population), poor symptom
control (ACT<18; 65%) or both (31%) at baseline. When
analysed as a continuous variable we did not ﬁnd a signiﬁcant
difference between treatment groups for AQLQ change in the
total study population, but there was a signiﬁcant difference in
the subgroups with highest treatment intensity, poor symptom
control or both.
Effects of TLA on objective markers of bronchial and systemic
allergy and lung function
TLA treatment was associated with a greater decrease in FENO
during the study than placebodmean difference  7.1 ppb (95%
CI  13.6 to  0.7; p¼0.03; table 3), which was of greater
Table 1 Characteristics of study patients at baseline, presented as mean (SD) unless otherwise stated
Patients randomly allocated to treatment (n[312) Patients in primary efﬁcacy analysis (n[282)
Active (n[207) Placebo (n[105) Active (n[189) Placebo (n[93)
Age (years) 24.2 (16.1) 24.2 (15.6) 24.7 (16.1) 24.9 (16.0)
Age <12, n (%) 51 (25%) 26 (25%) 46 (24%) 22 (24%)
Male sex, n (%) 117 (57%) 50 (48%) 107 (57%) 44 (47%)
Country:
Sweden, n (%) 99 (48%) 51 (49%) 91 (48%) 47 (51%)
Denmark, n (%) 33 (16%) 22 (21%) 32 (17%) 22 (24%)
UK, n (%) 34 (16%) 19 (18%) 30 (16%) 13 (14%)
Germany, n (%) 23 (11%) 11 (11%) 23 (12%) 10 (11%)
Norway, n (%) 7 (3%) 0 (0%) 7 (4%) 0 (0%)
Finland, n (%) 6 (3%) 1 (1%) 6 (3%) 1 (1%)
BMI (kg/m
2) of adults (>18) 25.8 (4.4) 25.8 (5.2) 25.8 (4.5) 25.7 (5.4)
Duration of asthma (years) 14.6 (12.8) 12.1 (10.5) 14.8 (12.9) 11.7 (10.6)
AQLQ* 4.20 (0.96) 4.27 (0.96) 4.21 (0.92) 4.25 (0.97)
FEV1 (% predicted) 89.6 (17.7) 91.8 (16.9) 89.9 (17.6) 91.2 (15.3)
PEF (% predicted) 92.7 (18.8) 92.5 (22.0) 93.3 (18.6) 92.5 (21.3)
FEF50 (% predicted) 71.3 (27.9) 71.2 (30.4) 71.4 (28.1) 72.4 (29.7)
FENO (ppb) 37.3 (38.0) 34.0 (34.1) 38.5 (38.6) 34.5 (33.3)
Eosinophil count (%) 0.45 (0.62) 0.45 (0.56) 0.45 (0.62) 0.45 (0.56)
ACT score 15.7 (3.9) 16.1 (3.5) 15.8 (3.7) 15.9 (3.5)
Inhaled corticosteroid dosey 586 (445) 610 (372) 576 (368) 616 (376)
House dust mite sensitised, n (%)z 133 (66%) 70 (695) 127 (67%) 64 (69%)
IgE Der. pteronyssinus, median (IQR) 3.9 (0.3, 32.7) 4.1 (0.3, 37.3) 3.9 (0.3, 32.7) 4.1 (0.3, 37.3)
IgE Der. farinae, median (IQR) 4.0 (0.3, 31.1) 3.9 (0.3, 29.8) 4.0 (0.3, 31.1) 3.9 (0.3, 29.8)
Cat sensitised, n (%)z 139 (69%) 73 (72%) 127 (67%) 66 (71%)
IgE cat, median (IQR) 2.0 (0.3, 10.6) 1.0 (0.3, 5.1) 2.0 (0.3, 10.6) 1.0 (0.3, 5.1)
Dog sensitised, n (%)z 118 (59%) 61 (60%) 109 (58%) 56 (60%)
IgE dog, median (IQR) 1.1 (0.3, 5.4) 0.8 (0.3, 3.8) 1.1 (0.3, 5.4) 0.8 (0.3, 3.8)
Seasonal allergen sensitised, n (%)x 87 (43%) 43 (42%) 85 (45%) 38 (41%)
Total IgE, median (IQR) 281 (109, 662) 257 (120, 506) 281 (109, 662) 257 (120, 506)
Rhinitis, n (%) 191 (95%) 98 (96%) 180 (95%) 88 (95%)
Eczema, n (%) 49 (24%) 18 (17%) 45 (24%) 17 (18%)
Food allergy, n (%) 28 (14%) 8 (8%) 23 (12%) 7 (8%)
All IgE levels are in kU/litre.
*AQLQ¼mini-AQLQ for those aged $12 years, PAQLQ for those <12 years.
yInhaled corticosteroid dose is beclomethasone dipropionate equivalent daily dose.
zSensitised¼speciﬁc IgE level $0.70 KU/litre or positive skin prick test (weal diameter to allergen $ weal diameter of positive control) to the relevant allergen, taken within 2 years of study
enrolment (1 year if #12 years).
xSeasonal allergen¼grass pollen, birch pollen, mugwort or mould.
ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; BMI, body mass index; Der. farinae, Dermatophagoides farina; Der. pteronyssinus, Dermatophagoides pteronyssinus;
FEF50, forced expiratory ﬂow at 50% of vital capacity; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; PAQLQ, Paediatric Asthma Quality of Life Questionnaire; PEF,
peak expiratory ﬂow.
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Asthma and the environmentmagnitude in patients with abnormally raised FENO (>45 ppb)
at baseline (mean difference  29.7 ppb; 95% CI  47.2 to  12.2;
p¼0.001). There was no signiﬁcant difference in blood eosino-
phil counts between treatment groups. We found a rise in cat-
speciﬁc IgE levels relative to baseline level in the placebo group
(mean 35%; 95% CI 18% to 53%) and a signiﬁcantly smaller rise
in the active group (mean 8%; 95% CI 0 to 17%; p¼0.01; table
3). Lesser increases in levels of speciﬁc IgE to house dust mite
and dog allergens were also seen in the active versus the placebo
group, but the differences between groups were not statistically
signiﬁcant. There was no signiﬁcant difference between groups
in total IgE level change during the study, nor in measures of
lung function FEV1, FEF50 or PEF (table 3).
Effects of TLA on other asthma medication use and asthma
exacerbation rates
Although this study was not primarily designed to evaluate TLA
effects on asthma medication use or asthma exacerbation rates,
medication use and exacerbations by treatment group are
presented in online table S4. These data show relatively low
rates of severe asthma exacerbations, no signiﬁcant difference
between groups in use of asthma medications and no signiﬁcant
difference between groups in asthma exacerbation rates.
15 When
exacerbation data were analysed according to predeﬁned
subgroups, there was no signiﬁcant difference in rate of asthma
exacerbations for the whole study population (mean 0.17 TLA;
0.24 placebo; p¼0.50), for those with ACT<18 at baseline (mean
0.18 TLA; 0.34 placebo; p¼0.28), for those with GINA 4 treat-
ment intensity at baseline (mean 0.24 TLA; 0.40 placebo;
p¼0.23) or for those with both ACT<18 and GINA 4 at baseline
(mean 0.23 TLA; 0.57 placebo; p¼0.07).
Adverse events
In total, 153 (74%) patients in the active and 79 (75%) in the
placebo group suffered an adverse event, and 32 (17%) patients
in the active and 14 (15%) in the placebo group a serious adverse
event. None were treatment related. Further details are given in
the online supplementary material.
Adults and children assessed 
for eligibility (n=388)
Randomised n=312
Active group n=207 Placebo group n=105
Ineligible n=74
Declined to participate n=2
Device installed n=189 Device installed n=93
Consent withdrawn:
- 4 disturbed by sound 
- 5 other reasons
Lost to follow-up n=1
3-month visit: n=175 3-month visit: n=83
Consent withdrawn:
- 4 disturbed by draught
- 3 disturbed by sound
- 6 other reasons
Lost to follow-up n=1
Consent withdrawn:
- 2 disturbed by sound
- 2 other reasons
12-month visit: n=166 12-month visit: n=79
Consent withdrawn:
- 2 disturbed by sound
- 5 other reasons
Lost to follow-up n=2
Consent withdrawn n=4
Protocol violation n=12
Lost to follow-up n=1
Unable to install device due to 
limited space in bedroom n=1
Consent withdrawn n=3
Protocol violation n=7
Lost to follow-up n=1
Unable to install device due to 
limited space in bedroom n=1
Figure 1 Participant ﬂow through the trial.
Figure 2 Treatment response rate in patients treated with temperature
controlled laminar airﬂow (TLA) or a placebo device for 1 year, deﬁned
as an increase in Asthma Quality of Life Questionnaire score of either
$0.5 or $1.0 point. Data are shown for the total study population
(n¼282), those with high treatment intensity at baseline (Global
Initiative for Asthma, GINA 4; n¼129), poor asthma control at baseline
(Asthma Control Test, ACT<18; n¼184) or both (GINA4/ACT<18;
n¼87). *p<0.05, **p<0.01 relative to placebo.
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Despite advances in asthma treatment, a signiﬁcant number of
patients have asthma that remains poorly controlled.
17 Previous
studies of allergen avoidance measures for treating asthma have
been disappointing, leading the authors of a recent Cochrane
systematic review of house dust mite control measures for
asthma to comment ‘it is doubtful whether further studies. are
worthwhile’.
8 In this trial we investigated the effects of a novel
treatment using nocturnal TLA in the homes of patients with
atopic asthma. Contrary to previous studies, we found that
exposure control using TLA treatment at night has an impact on
overall asthma-related quality of life, with a signiﬁcant
Table 2 Asthma-related quality of life in active and placebo groups after 1 year of treatment
Active Placebo Difference (95% CI)* OR (95% CI)* p Value*
AQLQ responders $0.5y
Intention to treat, n/N (%) 143/189 (76%) 56/92 (61%) 14.8% (3% to 27%) 1.92 (1.09 to 3.38) 0.02
Per protocol, n/N (%)z 106/136 (77%) 40/66 (61%) 16.6% (3% to 30%) 2.22 (1.11 to 4.40) 0.02
<12 years, n/N (%) 37/46 (80%) 14/22 (64%) 16.8% (8% to 38%) 5.57 (1.13 to 27.48) 0.04
$12 years, n/N (%) 106/143 (74%) 42/70 (60%) 14.1% (1% to 28%) 1.89 (0.98 to 3.65) 0.06
GINA 4 group, n/N (%)x 63/82 (77%) 29/47 (62%) 15.1% (2% to 31%) 2.42 (1.05 to 5.60) 0.04
Poorly controlled, n/N (%){ 93/125 (74%) 30/58 (52%) 22.7% (8% to 38%) 3.45 (1.66 to 7.20) <0.001
GINA 4 poorly controlled, n/N (%)** 43/57 (75%) 15/30 (50%) 25.4% (4% to 47%) 4.74 (1.48 to 15.19) 0.009
AQLQ responders $1.0y
Intention to treat, n/N (%) 119/189 (63%) 47/92 (51%) 14.8% (3% to 26%) 1.58 (0.93 to 2.69) 0.09
Per protocol, n/N (%)z 89/136 (65%) 33/66 (50%) 15.4% (1% to 30%) 1.85 (0.97 to 3.53) 0.06
<12 years, n/N (%) 33/46 (72%) 11/22 (50%) 21.7% ( 3% to 46%) 4.40 (0.99 to 19.57) 0.05
$12 years, n/N (%) 86/143 (60%) 36/70 (51%) 8.7% ( 5% to 23%) 1.37 (0.74 to 2.52) 0.31
GINA 4 group, n/N (%)x 51/82 (62%) 24/47 (51%) 15.1% (2% to 31%) 1.96 (0.87 to 4.40) 0.10
Poorly controlled, n/N (%){ 77/125 (62%) 24/58 (41%) 20.2% (5% to 35%) 2.78 (1.36 to 5.67) 0.005
GINA 4 poorly controlled, n/N (%)** 37/57 (65%) 11/30 (37%) 28.2% (7% to 49%) 8.81 (2.14 to 36.32) 0.003
Change in AQLQ symptom domain
Intention to treat 1.32 (1.23) 0.99 (1.38) 0.31 (0.01 to 0.61) 0.04
Per protocolz 1.34 (1.14) 0.96 (1.34) 0.36 (0.01 to 0.71) 0.04
<12 years 1.46 (1.36) 0.93 (1.49) 0.38 ( 0.34 to 1.10) 0.29
$12 years 1.27 (1.18) 1.01 (1.36) 0.28 ( 0.62 to 0.05) 0.10
GINA 4 groupx 1.45 (1.14) 1.00 (1.44) 0.47 (0.03 to 0.91) 0.04
Poorly controlled{ 1.41 (1.24) 0.95 (1.60) 0.58 (0.17 to 0.98) 0.006
GINA 4 poorly controlled** 1.45 (1.15) 0.86 (1.70) 0.70 (0.13 to 1.26) 0.02
*Adjusted analyses controlled for country, gender, years since asthma diagnosis, GINA treatment intensity step at baseline, and AQLQ value at baseline.
yImprovement was classiﬁed as $0.5 or $1.0 point increase in ‘AQLQ’ (¼mini-AQLQ or PAQLQ) between installation of nocturnal TLA device and assessment 1 year later.
zPer protocol analyses excluded patients with consent withdrawn and/or with <80% treatment compliance (n¼50 active; 27 placebo).
xAsthma treatment intensity at baseline classiﬁed according to GINA 2006
12 where GINA step 4 is high treatment intensity.
{Poorly controlled asthma was deﬁned as ACT score <18 at baseline.
**Poorly controlled asthma in combination with high treatment intensity.
ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; GINA, Global Initiative for Asthma; PAQLQ, Paediatric Asthma Quality of Life Questionnaire.
Figure 3 Change in Asthma Quality of Life Questionnaire (AQLQ) score during 1 year of temperature controlled laminar airﬂow (TLA) (blue line) or
placebo (dotted red line) treatment in the whole population (All), those with highest asthma treatment intensity at baseline (Global Initiative for Asthma,
GINA 4), those with poor asthma control at baseline (Asthma Control Test, ACT<18), or both (GINA 4, ACT<18). Values are mean 61 SEM. Baseline
AQLQ scores were similar in the TLA and placebo groups (total group mean 4.21 TLA, 4.25 placebo; GINA 4 mean 4.14 TLA, 4.14 placebo; ACT<18
mean 3.97 TLA, 3.92 placebo; GINA 4, ACT<18 mean 4.01 TLA, 3.85 placebo).
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rate between active and placebo groups. The reason that
nocturnal TLA is successful where so many other approaches
have failed may be the profound reduction in inhaled aero-
allergen exposure which this treatment achieves. The beneﬁcial
effects of TLA treatment on quality of life were not restricted to
a speciﬁc age group of the study population, although when
those aged $12 years (on whom the study was powered) were
analysed alone, the effect of treatment was of borderline
statistical signiﬁcance. The treatment effect did appear to be
greatest in patients with a combination of high asthma treat-
ment intensity and poor asthma control, who represent
a signiﬁcant area of unmet need. Nocturnal TLA treatment also
led to reduced airway inﬂammation measured by FENO,
particularly in patients with abnormally raised FENO (>45 ppb)
prior to treatment, and interestingly led to modiﬁed progression
of some allergen-speciﬁc IgE compared with placebo. The lesser
increase in cat allergen-speciﬁc IgE raises the intriguing possi-
bility that nocturnal exposure control may lead to longer-term
downregulation of allergic immune responses which has not
previously been reported. Given the close relationship between
allergen exposure, IgE sensitisation and airway inﬂammation,
these data suggest that nocturnal TLA may work through
exclusion of aeroallergens from the breathing zone.
18 19 We did
not ﬁnd any effect of TLA treatment on measures of lung
function such as FEV1 and PEF, and this is consistent with
previous studies which showed that avoidance of aeroallergens
can have beneﬁcial effects on asthma symptoms and measures of
airway inﬂammation without affecting lung function.
47This
study was designed to evaluate the effect of TLA on self-reported
quality of life, and the small numbers of patients with acute
asthma exacerbations during the study limited our power to
evaluate whether TLAtreatment reduces exacerbation rates. The
effects of TLA on quality of life and FENO are consistent with
previous pilot work using TLA.
20 The clinical effects of
nocturnal TLA treatment appear to be applicable to a broad
patient group, because our study population included a wide age
range of patients sensitised to a variety of perennial allergens,
recruited in six countries. Our inclusion criteria for the study
were broad, and did not demand formal demonstration of vari-
able airway obstructiondthe trial results can therefore be
generalised to settings where an asthma diagnosis is made
without use of such criteria. It is however possible that
treatment outcomes would differ in a group of patients
with asthma included on the basis of meeting objective
physiological criteria for airway obstruction or bronchial
hyper-responsiveness. We found no evidence of a difference in
treatment efﬁcacy between children aged <12 and adolescents/
adults. Although the treatment effect in those aged $12 was of
borderline statistical signiﬁcance, the effect size was similar to
that seen in patients aged <12 and in the whole population. The
difference in response rate between treatment groups in those
aged $12 was not as large as the 20% difference which the study
was powered to detect, perhaps due to the very high response
rate in the placebo group. Overall our ﬁndings support other
evidence that nocturnal exposures have a signiﬁcant impact on
inﬂammation and symptoms in asthma.
21e23 This may be
a consequence of circadian changes in autonomic function,
steroid hormones and immune responsiveness. There is also
persistent aeroallergen exposure at night, due in part to aero-
allergen transfer to the breathing zone via body convection.
Together with other studies of TLA, our ﬁndings suggest that
the clinical effects of TLA can be explained by its ability to break
the persistent body convection and thereby reduce aeroallergen
exposure.
In conclusion we have demonstrated that nocturnal control of
aeroallergen exposure using a novel non-pharmacological treat-
ment TLA can improve quality of life and reduce airway
inﬂammation in adults and children with atopic asthma, without
signiﬁcant adverse effects. Moreover the treatment limited rises
in some aeroallergen-speciﬁc IgE levels, which have a close rela-
tionship with severity and persistence of asthma.
18 19 24
Nocturnal TLA may be a treatment option for patients with
uncontrolled atopic asthma despite high treatment intensity,
where guidelines recommend stepping up treatment.
10 Our
ﬁndings support the importance of focusing exposure control
interventions on the breathing zone, and highlight the role of
nocturnal exposures in precipitating airway inﬂammation and
symptoms in patients with atopic asthma.
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Table 3 Objective markers of bronchial inﬂammation and systemic allergy after 1 year of treatment
Active Placebo Difference (95% CI) p Value
ΔFENO  4.88 ( 9.3 to  0.4) 2.82 ( 3.5 to 9.2)  7.13 ( 13.6 to  0.7) 0.03
ΔFENO (high baseline FENO)*  27.30 ( 37.6 to  17.0)  2.53 ( 24.0 to 18.9)  29.70 ( 47.2 to  12.2) 0.001
Δ Eosinophil count (%)  0.06 ( 0.15 to 0.03)  0.02 ( 0.12 to 0.07)  0.04 ( 0.20 to 0.08) 0.42
Δ FEV1 (% predicted)  0.1 ( 1.6 to 1.4) 1.4 ( 0.9 to 3.6)  2.1 ( 4.6 to 0.5) 0.11
Δ PEF (% predicted) 2.6 (0.5 to 4.6) 5.1 (2.1 to 8.1)  2.2 ( 5.6 to 1.2) 0.20
Δ FEF50 (% predicted)  4.7 ( 8.8 to  0.5)  5.2 ( 11.6 to 1.2)  2.0 ( 8.4 to 4.5) 0.55
Total IgE 4.6 ( 3.5 to 12.6) 3.7 ( 4.1 to 11.5) 2.9 ( 9.9 to 15.7) 0.66
Δ Cat-speciﬁc IgE 8.2 ( 0.4 to 16.7) 35.4 (17.8 to 53.0)  26.0 ( 44.1 to  7.9) 0.005
Δ Dog-speciﬁc IgE  1.9 ( 10.4 to 6.5) 13.9 ( 10.0 to 38.2)  14.6 ( 36.5 to 7.3) 0.19
Δ Dust mite speciﬁc IgE
Der. farinae 3.5 ( 6.2 to 13.2) 13.6 ( 0.7 to 27.9)  8.2 ( 25.9 to 9.5) 0.36
Der. pteronyssinus  2.6 ( 9.7 to  4.5) 7.2 ( 5.4 to 19.8)  6.4 ( 20.1 to 7.3) 0.36
All data were calculated using last observation carried forward to impute missing values. Data are expressed as mean (95% CI) absolute changes in FENO (ppb), eosinophil count (as % of total
white cell count) and lung function variables (as % predicted value), and mean (95% CI) percentage change in total or speciﬁc IgE levels (kU/litre) relative to baseline level over the 1-year study
period.
*Analysis of change in FENO in the subgroup of patients with abnormally raised FENO (>45 ppb) at baseline. In this group the mean (SD) baseline FENO in ppb was active 81.8 (44.2; n¼56)
and placebo 80.8 (32.3; n¼23). For speciﬁc and total IgE and eosinophil counts, n¼175 active, 91 placebo; for all other analyses, n¼189 active, 93 placebo.
Der. farinae, Dermatophagoides farina; Der. pteronyssinus, Dermatophagoides pteronyssinus; FEF50, forced expiratory ﬂow at 50% of vital capacity; FENO, fractional exhaled nitric oxide; FEV1,
forced expiratory volume in 1 s; PEF, peak expiratory ﬂow.
220 Thorax 2012;67:215e221. doi:10.1136/thoraxjnl-2011-200665
Asthma and the environmentData and Safety Monitoring Committee Professor Jan Lo ¨tvall (Chair), Go ¨teborg
University, Sweden; Professor Stephen Durham, National Heart and Lung Institute,
Imperial College London, UK; Fredrik Hansson, Commitum AB.
*4A Study Group Members Robert Boyle, NIHR Biomedical Research Centre,
Imperial College Healthcare NHS Trust and Imperial College London, UK; Christophe
Pedroletti, Pa ¨ivi So ¨derman and Bjo ¨rn Nordlund, Karolinska University Hospital Solna,
Sweden; Per Tunqvist and Magnus Wickman, Sach’s Children’s Hospital, Sweden;
Victoria Strand and Pa ¨r Gyllfors, Capio St Go ¨rans Hospital, Sweden; Janne Bjo ¨rkander,
County Hospital Ryhov, Sweden; Leif Bjermer and Stefan Willers, Lund University
Hospital, Sweden; Ann Hammarlund, Hospital of A ¨ngelholm, Sweden; Bill Hesselmar
and Nils A ˚berg, The Queen Silvia Children  s Hospital, Sweden; Erkka Valovirta and and
Heikki Valkama, Terveystalo Turku, Finland; Kai-Ha ˚kon Carlsen, Karin Lødrup Carlsen and
Egil Bakkeheim, Ulleva ˚l University Hospital, Norway; Malcolm Sue-Chu, Trondheim
University Hospital, Norway; Ronald Dahl, Aarhus University Hospital, Denmark; Vibecke
Backer and Lotte Harmsen, Bispebjerg Hospital, Denmark; Claudia Gore, and Heather
Hanna, Imperial College London, UK; Christian Virchow and Peter Julius, University of
Rostock, Germany; Erika Von Mutius and Caroline von Ehrenstein, University of Munich,
Germany; Andrea Von Berg and Christina Beckman, Marien-Hospital Wesel, Germany;
Per Olof Wernersson, Allergimottagningen Karlstad, Sweden; Uwe Schauer,
St Josef-Hospital Bochum, Germany; Olof Zetterstro ¨m and Ulla Nystro ¨m Kronander,
University Hospital of Linko ¨ping, Sweden; John Warner, NIHR Biomedical Research
Centre, Imperial College Healthcare NHS Trust, and Imperial College London, UK.
Acknowledgements We are grateful to the participants for their assistance in the
conduct of this clinical trial.
Funding The study was funded by Airsonett AB. Robert Boyle was supported by
a National Institute for Health Research Clinical Lectureship. John Warner is supported
by a National Institute for Health Research Senior Fellowship. Robert Boyle and John
Warner are supported by a National Institute for Health Research Biomedical Research
Centre, and by the MRC and Asthma UK Centre in Allergic Mechanisms of Asthma.
Competing interests None.
Ethics approval Ethics approval was provided by responsible institutional review
boards at each site in this multicentre international trial.
Contributors CP, MW, LB, EV, RD, AVB, OZ and JOW designed the study and
planned the analyses. All members of the 4A study group participated in patient
recruitment for the study. RJB wrote the manuscript with contributions from all
authors.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1. Tunnicliffe WS, Fletcher TJ, Hammond K, et al. Sensitivity and exposure to indoor
allergens in adults with differing asthma severity. Eur Respir J 1999;13:654e9.
2. Peroni DG, Boner AL, Vallone G, et al. Effective allergen avoidance at high altitude
reduces allergen-induced bronchial hyperresponsiveness. Am J Respir Crit Care Med
1994;149:1442e6.
3. Peroni DG, Piacentini GL, Costella S, et al. Mite avoidance can reduce air trapping
and airway inﬂammation in allergic asthmatic children. Clin Exp Allergy
2002;32:850e5.
4. Piacentini GL, Bodini A, Costella S, et al. Allergen avoidance is associated with
a fall in exhaled nitric oxide in asthmatic children. J Allergy Clin Immunol
1999;104:1323e4.
5. Piacentini GL, Peterson C, Peroni DG, et al. Allergen avoidance at high altitude and
urinary eosinophil protein X. J Allergy Clin Immunol 1999;104:243e4.
6. Grootendorst DC, Dahlen SE, Van Den Bos JW, et al. Beneﬁts of high altitude
allergen avoidance in atopic adolescents with moderate to severe asthma, over and
above treatment with high dose inhaled steroids. Clin Exp Allergy 2001;31:400e8.
7. Morgan WJ, Crain EF, Gruchalla RS, et al. Results of a home-based environmental
intervention among urban children with asthma. N Engl J Med 2004;351:1068e80.
8. Gotzsche PC, Johansen HK. House dust mite control measures for asthma.
Cochrane Database Syst Rev 2008;(2):CD001187.
9. Sublett JL, Seltzer J, Burkhead R, et al. Air ﬁlters and air cleaners: rostrum by the
American Academy of Allergy, Asthma & Immunology Indoor Allergen Committee.
J Allergy Clin Immunol 2009;125:32e8.
10. Global Strategy for Asthma Management and Prevention. Bethesda, MD: National
Heart Lung and Blood Institute, 2006.
11. Juniper EF, Guyatt GH, Cox FM, et al. Development and validation of the Mini
Asthma Quality of Life Questionnaire. Eur Respir J 1999;14:32e8.
12. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in
a disease-speciﬁc quality of life questionnaire. J Clin Epidemiol 1994;47:81e7.
13. American Thoracic Society, European Respiratory Society. ATS/ERS
recommendations for standardized procedures for the online and ofﬂine
measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005.
Am J Respir Crit Care Med 2005;171:912e30.
14. Anon. Standardization of spirometry, 1994 update. American Thoracic Society. Am J
Respir Crit Care Med 1995;152:1107e36.
15. Reddel HK, Taylor DR, Bateman ED, et al. An ofﬁcial American Thoracic Society/
European Respiratory Society statement: asthma control and exacerbations:
standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir
Crit Care Med 2009;180:59e99.
16. Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma
severity and control. Eur Respir J 2008;32:545e54.
17. Demoly P, Gueron B, Annunziata K, et al. Update on asthma control in ﬁve European
countries: results of a 2008 survey. Eur Respir Rev 2010;19:150e7.
18. Silvestri M, Pistorio A, Battistini E, et al. IgE in childhood asthma: relevance of
demographic characteristics and polysensitisation. Arch Dis Child 2010;95:979e84.
19. Matsui EC, Sampson HA, Bahnson HT, et al. Allergen-speciﬁc IgE as a biomarker of
exposure plus sensitization in inner-city adolescents with asthma. Allergy
2010;65:1414e22.
20. Pedroletti C, Millinger E, Dahlen B, et al. Clinical effects of puriﬁed air administered
to the breathing zone in allergic asthma: a double-blind randomized cross-over trial.
Respir Med 2009;103:1313e19.
21. Calhoun WJ. Nocturnal asthma. Chest 2003;123(3 Suppl):399Se405S.
22. Mahmic A, Tovey ER, Molloy CA, et al. House dust mite allergen exposure in
infancy. Clin Exp Allergy 1998;28:1487e92.
23. Vanlaar CH, Peat JK, Marks GB, et al. Domestic control of house dust mite allergen
in children’s beds. J Allergy Clin Immunol 2000;105:1130e3.
24. Craig TJ. Aeroallergen sensitization in asthma: prevalence and correlation with
severity. Allergy Asthma Proc 2010;31:96e102.
PAGE fraction trail=6.75
Thorax 2012;67:215e221. doi:10.1136/thoraxjnl-2011-200665 221
Asthma and the environment